<DOC>
	<DOCNO>NCT01004601</DOCNO>
	<brief_summary>Docetaxel pemetrexed validate previously treat advanced non-small cell lung cancer ( NSCLC ) ; however , tolerability concern docetaxel ( tri-weekly 75 mg/m2 schedule ) . The investigator conduct study compare efficacy toxicity weekly low-dose docetaxel versus tri-weekly pemetrexed previously treat advanced NSCLC .</brief_summary>
	<brief_title>Low Dose Weekly Docetaxel Versus Pemetrexed Previously Treated Advanced Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description>We follow schedule weekly low dose docetaxel ( 30 mg/m2 day 1 8 every 3 week ; 60 mg/m2 accumulate dose cycle ) hospital effort achieve good tolerability . We therefore perform exploratory study , statistical analysis , investigate efficacy toxicity low dose docetaxel schedule compare pemetrexed patient NSCLC fail previous chemotherapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>stage IIIb IV NSCLC previous treatment chemotherapy tyrosin kinase inhibitor performance status le 2 age less 18 year pregnancy performance status 34</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>pretreated failure advance stage IIIb/IV NSCLC</keyword>
</DOC>